NASDAQ is one of the biggest stock exchanges in the world by trading volume and lists some of the biggest companies. Here is a quick look at three companies that could be added to the watch lists.
The medical technology industry is hugely innovative and has naturally attracted the attention of investors in a big way. There are a number of companies that one could look into at this point, and one of those is Intelligent Bio Solutions Inc. (NASDAQ: INBS). The company offers fast, intelligent, and non-invasive testing solutions and is best known for its flagship Intelligent Fingerprinting Drug Screening Platform.
The company believes that its platform would be a game changer in the field of sweat analysis and could eventually have wide applications in other industries. The cost-effective platform had been designed in such a way as to detect the use of drugs in the workplace. Some of the drugs it can screen include cannabis, cocaine, methamphetamine, and opioids. The samples are collected in seconds, and a result is produced in less than ten minutes. Intelligent Bio Solutions also came up with the platform technology, which can test up to 130 indications.
Workplace safety is a major factor for most businesses, and especially so for certain industries in which a lack of safety can lead to grave consequences. Any kind of drug-induced impairment can lead to safety issues, and hence, quick workplace drug testing is a necessity nowadays. In fact, in certain industries, like construction, it can even lead to serious harm or fatalities. That is the market that Intelligent Bio Solutions seeks to serve with its Intelligent Fingerprinting Drug Screening Platform.
The platform offers a quick and dignified way of going about the process. Unlike most of the other platforms, the platform from the company is non-invasive and quick. The platform takes sweat from the fingertips and analyzes it for the presence of any drugs. The platform screens for many of the drugs, which can lead to impairment at the workplace.
Jaguar Health Inc. (NASDAQ:JAGX) is a commercial-stage pharmaceutical firm focused on the development of medicines meant for animals and human beings suffering from gastrointestinal problems. Jaguar Health Inc. is especially focused on impairing and chronic diarrhea. It conducts its operations primarily through two segments: animal health and human health. One of its well-known products is Mytesi, which provides relief from non-infectious forms of diarrhea in adults suffering from AIDS.
On October 12, Jaguar Health announced that its founder, Chief Executive Officer, and President, Lisa Conte, would make presentations and have one-on-one meetings with investors at an event. The event is the Lytham Partners Fall 2023 Investor Conference, which would take place virtually at the BIO Investor Forum on October 17 and 18. The company revealed that a webcast of the presentation would be made available on October 17. Conte would participate in one-on-one meetings throughout the event.
Atreca Inc. (NASDAQ: BCEL) is a clinical-stage biotech company involved in the development of unique therapeutics that are generated by virtue of its novel discovery platform. The basis of the platform is the interrogation of the active human immune response. On September 21, Atreca Inc. announced that it had entered into an agreement to terminate its lease for its headquarters located in San Carlos, California.
The move was part of the active efforts of the company to cut its operating expenses, and the lease was worth around $13 million in yearly expenses. In the news release, the company also revealed that on September 22, 2023, Chief Financial Officer Herb Cross was going to leave Atreca. However, it was also noted that Cross was going to serve the company in the capacity of consultant up until the first fiscal quarter of 2024.
Cardio Diagnostic Holdings Inc. (NASDAQ: CDIO) The pioneering company is known for artificial intelligence-powered cardiovascular medicine tests. On October 12, Cardio Diagnostic Holdings Inc. announced that it had launched its new integrated facility located in Iowa City, Iowa. The new facility would include the company’s high-complexity Clinical Laboratory Improvement Amendments (CLIA) lab, fulfillment center, and a new research lab.
The facility would be the hub for the distribution of sample collection kits to Cardio Diagnostic’s clients and for all forms of research and commercial-level testing. The operations at the facility would initially begin at some point in the fourth fiscal quarter of 2023. Full operations could begin in the first quarter of 2024. The high-complexity CLIA lab has a modular setup and would be able to process nearly 10,000 tests a month. It would also help in cutting down on lab processing costs, which make up the biggest portion (up to 60%) of the costs of selling goods.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.